Combined modality therapy for stage III non-small-cell lung cancer

Seminars in Radiation Oncology

Volumn 20, Issue 3, 2010, Pages 186-191

  Anderson, Cynthia S ^a   Curran, Walter J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PLACEBO; SUNITINIB; VINBLASTINE; VINDESINE;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; DRUG MECHANISM; DRUG SAFETY; ESOPHAGITIS; ESOPHAGUS DISEASE; HEMOPTYSIS; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PATIENT CARE; PERICARDITIS; PNEUMONIA; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PREOPERATIVE CARE; RADIOTHERAPY, ADJUVANT;

EID: 77954841444     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2010.01.007     Document Type: Review

References (41)

1. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
2. Vallières E., Shepherd F.A., Crowley J., et al. The IASLC lung cancer staging project: Proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009, 4:1049-1059.
3. Cancer Staging Manual 2002, AJCC, Springer-Verlag, New York, NY. (ed 6).
4. Depierre A., Milleron B., Moro-Sibilot D., et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002, 20:247-253.
5. Perez C.A., Stanley K., Rubin P., et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 1980, 45:2744-2753.
6. Roth J.A., Fosella F., Komaki R., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIa non-small cell lung cancer. J Natl Cancer Inst 1994, 86:673-680.
7. Rosell R., Gomez-Codina J., Camps C., et al. A randomized trial comparing perioperative chemotherapy plus surery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994, 330:153-158.
8. Depierre A., Milleron B., Moro-Sibilot D., et al. Perioperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0). II, And IIIa non-small cell lung cancer. J Clin Oncol 2002, 20:247-253.
9. Pisters K., Vallieres E., Bunn P., et al. S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results. Proc Am Soc Clin Oncol 2005, 23:16S.
10. Albain K.S., Rusch V.W., Crowley J.J., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995, 13:1880-1892.
11. Albain K.S., Swann R.S., Rusch V.W., et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet 2009, 1:379-386.
12. Van Meerbeeck J.P., Kramer G.W.P., Van Schil P.E.Y., et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIa non-small cell lung cancer. J Natl Cancer Inst 2007, 99:442-450.
13. Curran W.J., Scott C.B., Langer C.J., et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresectable stage III NSCLC. Proc Am Soc Clin Oncol 2003, 22:621.
14. Dillman R.O., Seagren S.L., Propert K.J., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 1990, 323:940-945.
15. Albain K.S., Crowley J.J., Turrisi A.T., et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002, 16:3454-3460.
16. Schaake-Koning C., van den Bogaert W., Delasio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992, 326:524-530.
17. Sause W., Kolesar P., Taylor S., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000, 117:358-364.
18. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized trials. BMJ 1995, 311:899-909. Non-Small Cell Lung Cancer Collaborative Group.
19. Auperin A., Le Pechoux C., Pignon J.P., et al. Concomitant radio-chemotherapy based on plating compounds in patients with locally advanced non-small cell lung cancer (NSCLC). A meta-analysis of individual data from 1764 patients. Ann Oncol 2006, 17:473-483. on behalf of the Meta-Analysis of Cisplatin/Carboplatin Based Concomitant Chemotherapy in Non-Small Cell Lung Cancer (MAC3-LC) Group.
20. Le C.T., Arriagada R., Tarayre M., et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 1992, 84:58.
21. Furuse K., Fukuoka M., Nishiyaki Y., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
22. Pierre F., Maurice P., Gilles R., et al. A randomized phase III Trial of sequential chemoradiotherapy versus concurrent chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC) (GLOT-GFPC NPC95-01) Pro. Am Soc Clin Oncol 2001, 20:312A.
23. Vokes E., Herndon J., Turrisi A. Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial. Proc Am Soc Clin Oncol 2004, 23:616A.
24. Belani C.P., Choy H., Bonomi P., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small cell lung cancer: A randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005, 23:5883-5891.
25. Belderbos J., Uitterhoeve L., van Zandwijk N., et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer. Eur J Cancer 2007, 43:114-121.
26. Pu A.T., Harrison A.S., Robertson J.M., et al. The toxicity of elective nodal irradiation in the definitive treatment of non-small cell carcinoma of the lng. Int J Radiat Oncol Biol Phys 1997, 39:196.
27. Senan S., De Ruysscher D., Giraud P., et al. Literature-based recommendations for treatment planning and exection for high-precision radiotherapy in lung cancer. Radiother Oncol 1997, 71:139-146.
28. Yuan S., Sun X., Li M., et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 2007, 30:239-244.
29. Socinski M.A., Schell M.J., Peterman A., et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002, 20:1335-1343.
30. Rosenman J.G., Halle J.S., Socinski M.A., et al. High-dose conformal radiotherapy for treatment of stage IIIA/B non-small cell lung cancer: Technical issues and results for a phase I/II trial. Int J Radiat Oncol Biol Phys 2002, 54:348-356.
31. Bradley J., Graham M.V., Winter K., et al. Phase I results of RTOG 0117: A phase I/II dose intensification study using 3D-CRT and concurrent chemotherapy for patients with inoperable non-small cell lung cancer. J Clin Oncol 2005, 23. 16S 7063.
32. Schild S., McGinnis W.L., Graham D., et al. Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2006, 65:1106-1111.
33. Socinski M., Rosenman J., Halle J., et al. Dose escalating conformal thoracic radiation therapy with induction concurrent carboplatin/paclitaxel in unresectable stage IIIa and IIIb non-small cell lung cancer: A modified phase I/II trial. Cancer 2001, 92:1213-1223.
34. Bradley J., Schild S., Bogart J., et al. RTOG 0617/ NCCTG N0628/ CALGB 30609/ ECOG R0617: A randomized phase III comparison of standard-dose (60 Gy) versus High-Dose (74 Gy) conformal radiotherapy with concurrent and consolidation carboplatin/paclitaxel +/- cetuximab (IND #103444) in patients with stage IIIa/IIIb non-small cell lung cancer Accessed October 30, 2009. http://www.rtog.org.
35. Kelly K., Chansky K., Gaspar L., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer: SWOG S0023. J Clin Oncol 2008, 26:2450-2456.
36. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
37. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
38. Perez-Soler R., Chachoua A., Hammond L., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22:3238-3247.
39. Riely G.J., Rizvi N.A., Kris M.G., et al. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:264-270.
40. Lynch T.J. A randomized multicenter phase III study of cetuximab (Erbitux) in combination with taxane/ carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC): B3-03. J Thorac Oncol 2007, 2:S340-S341.
41. Blumenschein G.R., Paulus R., Curran W.J., et al. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial. Proc Am Soc Clin Oncol 2008, 26:15S. (abst).